Diarrhea
Xifaxan generic may be stalled until 2029 despite tentative FDA approval
Although the FDA has granted tentative approval to Norwich Pharmaceuticals’ 200 mg generic rifaximin, Bausch Health asserted in a company statement that full approval will not be given until its own rifaximin patent expires in 2029.
Top 7 in FDA news: Approvals for diarrhea relief, endoscopic devices, Crohn’s treatment
Healio presents the following collection of FDA news related to gastroenterology, including the approval of generic diarrhea relief tablets, treatment for acid sphingomyelinase deficiency and biliary tract cancer, and more.
FDA approves Granules India Limited’s generic diarrhea relief tablets
Granules India Limited received FDA approval of its abbreviated new drug application for loperamide hydrochloride and simethicone tablets indicated for diarrhea symptom relief, according to a press release.
‘The water is recycled’: Splash pads reduce child drowning risk, boost diarrhea outbreaks
Splash pads for children at water parks offer less risk for drowning, but inadequate disinfection and poor toileting/hygiene skills create a hub for gastrointestinal illness outbreaks, noted data in Morbidity and Mortality Weekly Report.
Q&A: Liraglutide outperforms colesevelam in reducing stool frequency in bile acid diarrhea
Liraglutide reduced stool frequency in a small subset of patients with bile acid diarrhea and warrants consideration as a potential new treatment modality, according to research in The Lancet Gastroenterology and Hepatology.
Gut microbiota dysbiosis ‘unspecific’ to microscopic colitis, shared by diarrheal diseases
Although a feature in microscopic colitis, gut microbiota dysbiosis was also observed in functional and bile acid diarrhea, indicating fecal microbial changes are not due to the disease itself, researchers noted in BMC Gastroenterology.
AGA proposes first pharmacologic treatment plan for patients with IBS-C, IBS-D
The AGA has issued clinical guidelines that outline a pharmacologic treatment plan for patients with irritable bowel syndrome and its subtypes, IBS-constipation and IBS-diarrhea, which were published in Gastroenterology.
Intestinal absorbent improves short-term stool consistency, abdominal pain in IBS-D
SAN DIEGO — Enterosgel, a CE-certified intestinal absorbent, reduced short-term symptoms of stool consistency and abdominal pain among patients with irritable bowel syndrome with diarrhea, according to research.
IBS Awareness Month: Diagnostic tips, treatment options, multidisciplinary care and more
April is IBS Awareness Month and highlights the importance of public awareness and health messages about the diagnosis, treatment and quality of life for patients with irritable bowel syndrome.